Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date in this patient population, is being presented on Saturday, July 9 at the International TSC Research Conference in Washington, D.C.

Currently, Afinitor is approved in the US for the following indication: to treat patients with SEGA associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical intervention. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Additionally, the indication states, clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown(7).

Tuberous sclerosis complex affects approximately 25,000 to 40,000 people in the US and one to two million people worldwide, and is associated with a variety of resulting disorders including seizures, swelling in the brain (hydrocephalus), developmental delays and skin lesions(2,6). Also known as tuberous sclerosis (TS), TSC is a genetic disorder that may cause non-cancerous tumors to form in vital organs and can affect many different parts of the body, most commonly the brain and kidney(6,8). Signs and symptoms of TSC vary depending on which system and which organs are involved(6). SEGAs occur in up to 20% of patients with TSC. In countries where everolimus is not approved, brain surgery is the only treatment option for patients with growing SEGAs(2).

The 117-patient, randomized, placebo-controlled Phase III EXIST-1 (EXamining everolimus In a Study of TSC) trial met its primary endpoin
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
(Date:9/18/2014)... Australia , Sept. 18, 2014 Veterinary ... of Dr. Ashraf Hanna , M.D., Ph.D., and ... Board of Directors. Dr. Hanna is the Vice President ... Chief Financial Officer for the Genentech Foundation, while Dr. ... Head of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... , Sept. 18, 2014   Regulus Therapeutics ... biopharmaceutical company leading the discovery and development of ... initiated its ATHENA natural history of disease study ... kidney disease with no approved therapy. The ATHENA ... of renal function markers such as Glomerular Filtration ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... , BOCA RATON, Fla., Nov. 16 CPG has ... Management (PLM) Release 9.3 at Avema Pharma Solutions, a division ... operation of pharmaceutical, over-the-counter (OTC), and nutritional solid-dose products based ... live at Avema on September 28, 2009. "As a contract ...
... , JAMAICA PLAIN, Mass., Nov. 16 ... presentation today at the AACR-NCI-EORTC International Conference Molecular Targets ... efficiently penetrates the blood brain barrier and may be ... Olaf van Tellingen, Ph.D. of The Netherlands Cancer Institute, ...
Cached Medicine Technology:CPG Implements First-Ever Agile PLM Release 9.3 at Avema Pharma Solutions 2Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 2Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics 3
(Date:9/18/2014)... drink less sugar, according to a new study from ... enough, the study goes on to say, as all ... healthier at school , The research suggests a parent,s ... a child,s diet. , The study found Vancouver school ... per cent more likely to eat vegetables during the ...
(Date:9/18/2014)... 18, 2014 Relias Learning, the leader in ... services markets, today announced it has been named to the ... companies in America. , In the three-year period from 2010 ... almost 2,000 spots on the Inc. 5000 list to 1,025 ... , “The industries we serve continue to grow, and the ...
(Date:9/18/2014)... Gables, FL (PRWEB) September 18, 2014 ... a portion of proceeds to Feeding America Eastern Wisconsin. ... Days, 7 Ways to Save” with Turbana bananas and ... be two for $4 and Turbana bananas will be ... $1 for every two Fyffes pineapples that are purchased ...
(Date:9/18/2014)... T-System Inc. today announced Holyoke Medical Center ... EV™ for physicians — improving productivity ... solutions, Holyoke chose T-System’s solution because not only ... reimbursement, but also its ability to integrate with ... to capture emergency department, (ED) nurse documentation. , ...
(Date:9/18/2014)... Fit Body Boot Camp , an ... in the country and its popularity, as both a franchise ... enormously in 2014. , The company’s annual business conference, ... in Costa Mesa, CA on September 26 and 27, and ... Founder Bedros Keuilian, who is also considered the leading fitness ...
Breaking Medicine News(10 mins):Health News:Kids eat better if their parents went to college 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners with Sendik's Food Market to Donate Portion of Proceeds to Local Hunger-Relief Non-Profit 3Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... arteries remains the leading cause of disease and death in ... Medicine researcher is helping to open new pathways toward treating ... of biomedical sciences, is researching mutant forms of a human ... grow new blood vessels to restore blood flow in damaged ...
... Source Endurance is pleased to,announce that it ... Sports and,Fitness of San Marcos Texas to collaborate ... encompass several areas of,collaboration including the sharing and ... training approaches, and deployment of one,of the first ...
... Children,s Research Hospital have demonstrated that children with ... can retain normal function in both kidneys by ... when preoperative scans suggest that the tumors are ... St. Jude patients with bilateral Wilms tumor exhibiting ...
... Programs to be Marketed to Over 50,000 Members ... ... CANTEL MEDICAL,CORP. (NYSE: CMN ) and the National Safety Council ... prepare for the threat of a flu pandemic and similar,infectious diseases. The ...
... A SpaCapsule, Could Change The Outcome Of This ... Year,s Presidential Election, MIAMI, March 24 ... John McCain, Hillary Clinton and,Barack Obama,s stress levels are at an all ... city to city making,numerous public appearances. This can cause lack of sleep ...
... A study by a New York University dental research ... (gum) disease are more likely to develop gestational diabetes ... , The study, led by Dr. Ananda P. Dasanayake, ... NYU College of Dentistry, followed 256 women at New ...
Cached Medicine News:Health News:FSU researcher's 'mutant' proteins could lead to new treatment for heart disease 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 2Health News:Source Endurance and So High Sports Announce Research Alliance for Physiology and Human Performance 3Health News:St. Jude study offers new hope for children with kidney tumors deemed inoperable 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 2Health News:Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic 3Health News:Stress On The Campaign Trail, One Issue All The Candidates Agree On 2Health News:NYU dental researchers find evidence of periodontal disease leading to gestational diabetes 2
Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
Delicate strong curved serrated tips. Serrated handle with dull finish....
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Two 2.75 mm long tips separated 1 mm with 1 x 2 teeth. Serrated handle with dull finish....
Medicine Products: